You are receiving this email because you are subscribed to Behind the Markets. If you no longer wish to receive these emails, please unsubscribe here.
Dear Reader, Today I want to talk to you about my No. 1 takeover target… 
Those of you who have been around for a while will remember, in 2018, 2019 the biotech industry got hammered. And all of a sudden, these great companies that were creating incredibly novel, revolutionary treatments were seeing their stocks just get crushed. Like Loxo Oncology, Tesaro, Array Biopharma … I started to recommend them because they were just incredible bargains. All these companies were making breakthroughs in cancer – obviously a huge market, sadly. And as good as these companies were, they were getting hammered so hard they just started getting taken over. Big pharma, the “smart money” didn’t sit around – they were taking advantage of low prices! Loxo was bought by Eli Lilly three days after we recommended it. We recommended it Friday, it was taken over Monday. 
It was great! Tesaro was bought out by Glaxo 63 days after we recommended it … 
Array Biopharma was acquired by Pfizer shortly after we recommended it. 
And we are in one of those similar times now in the biotech sector. Even as the broader market has marched higher, biotech’s gotten hammered over the last six months! Even as AI is revolutionizing this sector … And even, especially biotechs that have new FDA-approved drugs on the market. Especially ones that could treat a BIG market … And especially ones focused on oncology, cancer. I’ll tell you, when a situation like this arises, we get as excited as Big Pharma does. It’s happening. And I’m pumped! Right now, the stock we’re so excited about is a company that just won FDA approval, two quarters ago, and the business is taking off. They’ve got the only drug for a certain type of solid tumor out there and they are just attacking the market. And we believe that this company, which has had takeover talks already with other big pharma giants like Gilead … Is a prime takeover target. And we’re not the only ones who believe this. Billionaire investors and insiders who specialize in biotech investing have been buying massive amounts of this stock. That’s why this opportunity is so urgent. And that’s why I went live for the first time in almost five years last night to tell you about it. But if you missed last night’s live event, because, let’s face it, life can get really life-y, my team made a replay available for you. Click here now to get, “Our No. 1 Takeover Target for November.” Honestly, this is my no. 1 takeover target all year. It’s such a no-brainer. But my team is taking this webinar replay offline this week, sooner than later, so don’t miss it. Click here now before this comes offline. My No. 1 takeover target is a really special opportunity I wanted to be sure we shared with you. It’s not every day you have an industry bear market beating down a great stock that’s dominating a big cancer market … That’s got billionaire insiders whaling up in anticipation of a takeover… And Big Pharma lining up offers. This is as good as it gets when it comes to these takeover deals. And our readers have done great with these – our win-rate is almost 100% on these deals for over 4 years running. Click here now to see “Our No. 1 Takeover Target” webinar before it comes offline. "The Buck Stops Here," 
P.S. This webinar is 100% FREE to watch. We’re giving away our “secret sauce” for picking takeovers. No matter what you decide, you will walk away wiser for watching. You can even grab a pen and paper and jot down some notes if you like. (It’s not every day we “open the kimono.”) But please, don’t miss it. Go here now for our replay before the link expires! | 
No comments:
Post a Comment